Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AAPGNASDAQ:ANABNASDAQ:APLSNYSE:OGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$29.75-0.5%$23.80$16.50▼$30.38$2.59BN/A56,280 shs9,082 shsANABAnaptysBio$23.60-1.5%$20.38$12.21▼$41.31$704.24M-0.26630,785 shs859,300 shsAPLSApellis Pharmaceuticals$19.27-1.6%$18.32$16.10▼$43.76$2.42B0.682.32 million shs3.25 million shsOGNOrganon & Co.$10.11+0.6%$10.16$8.01▼$23.10$2.63B0.583.39 million shs3.11 million shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International-0.50%+5.16%+22.93%+59.69%+2,974,999,900.00%ANABAnaptysBio-1.54%+10.95%+17.82%+40.14%-0.21%APLSApellis Pharmaceuticals-1.58%+4.11%+9.99%-20.93%-54.92%OGNOrganon & Co.+0.70%+5.92%+16.26%-32.48%-50.15%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/AN/AN/AN/AANABAnaptysBio1.7815 of 5 stars3.40.00.00.02.61.70.6APLSApellis Pharmaceuticals4.7675 of 5 stars4.33.00.04.43.92.50.6OGNOrganon & Co.4.7934 of 5 stars3.32.01.73.71.73.33.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAAPGAscentage Pharma Group International 3.00BuyN/AN/AANABAnaptysBio 2.80Moderate Buy$42.3879.56% UpsideAPLSApellis Pharmaceuticals 2.62Moderate Buy$40.05107.85% UpsideOGNOrganon & Co. 2.50Moderate Buy$18.0078.13% UpsideCurrent Analyst Ratings BreakdownLatest ANAB, AAPG, OGN, and APLS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/4/2025ANABAnaptysBioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$22.00 ➝ $38.006/2/2025APLSApellis PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$26.00 ➝ $29.005/29/2025ANABAnaptysBioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$40.005/28/2025ANABAnaptysBioGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$54.00 ➝ $90.005/22/2025APLSApellis PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$49.00 ➝ $41.005/22/2025OGNOrganon & Co.BNP ParibasSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/15/2025OGNOrganon & Co.Piper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$24.00 ➝ $18.005/14/2025APLSApellis PharmaceuticalsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$30.00 ➝ $20.005/9/2025APLSApellis PharmaceuticalsRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Outperform$75.00 ➝ $52.005/9/2025APLSApellis PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$41.00 ➝ $23.005/8/2025APLSApellis PharmaceuticalsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$21.00 ➝ $18.00(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAAPGAscentage Pharma Group International$980.65M2.64N/AN/AN/A∞ANABAnaptysBio$111.87M6.20N/AN/A$3.32 per share7.11APLSApellis Pharmaceuticals$775.84M3.12N/AN/A$1.64 per share11.75OGNOrganon & Co.$6.29B0.42$3.24 per share3.12($0.27) per share-37.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAAPGAscentage Pharma Group InternationalN/AN/A0.00∞N/AN/AN/AN/AN/AANABAnaptysBio-$163.62M-$4.85N/AN/AN/A-289.75%-287.94%-37.25%8/4/2025 (Estimated)APLSApellis Pharmaceuticals-$528.63M-$1.79N/AN/AN/A-34.97%-103.11%-28.96%7/30/2025 (Estimated)OGNOrganon & Co.$864M$2.883.032.700.9013.49%431.62%8.03%8/5/2025 (Estimated)Latest ANAB, AAPG, OGN, and APLS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025APLSApellis Pharmaceuticals-$0.36-$0.74-$0.38-$0.74$197.61 million$149.90 million5/5/2025Q1 2025ANABAnaptysBio-$1.30-$1.28+$0.02-$1.28$15.27 million$27.77 million5/1/2025Q1 2025OGNOrganon & Co.$0.89$1.02+$0.13$0.33$1.53 billion$1.51 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/AANABAnaptysBioN/AN/AN/AN/AN/AAPLSApellis PharmaceuticalsN/AN/AN/AN/AN/AOGNOrganon & Co.$0.080.79%+25.99%2.78%N/ALatest ANAB, AAPG, OGN, and APLS DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/2/2025OGNOrganon & Co.quarterly$0.020.8%5/12/20255/12/20256/12/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAAPGAscentage Pharma Group InternationalN/AN/AN/AANABAnaptysBioN/A10.2310.23APLSApellis Pharmaceuticals1.914.363.73OGNOrganon & Co.17.731.701.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAAPGAscentage Pharma Group InternationalN/AANABAnaptysBioN/AAPLSApellis Pharmaceuticals96.29%OGNOrganon & Co.77.43%Insider OwnershipCompanyInsider OwnershipAAPGAscentage Pharma Group InternationalN/AANABAnaptysBio33.50%APLSApellis Pharmaceuticals6.50%OGNOrganon & Co.1.96%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAAPGAscentage Pharma Group International60087.11 millionN/AN/AANABAnaptysBio10029.38 million20.17 millionOptionableAPLSApellis Pharmaceuticals770125.68 million115.93 millionOptionableOGNOrganon & Co.10,000259.96 million253.93 millionNot OptionableANAB, AAPG, OGN, and APLS HeadlinesRecent News About These CompaniesClass Action Alert: Levi & Korsinsky Reminds Organon (OGN) Investors of July 22, 2025 DeadlineJune 12 at 7:15 AM | accessnewswire.comOGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Organon & Co. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!June 12 at 7:00 AM | accessnewswire.comOrganon & Co. Class Action: The Gross Law Firm Reminds Organon Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2025 - OGNJune 12 at 5:45 AM | prnewswire.comClass Action Lawsuit Filed: Organon & Co. (OGN) – Join by July 22, 2025 - Contact Levi & KorsinskyJune 11 at 11:05 PM | accessnewswire.comORGANON SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Organon & Co. - OGNJune 11 at 10:57 PM | investing.comORGANON SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Organon & Co. - OGNJune 11 at 10:39 PM | globenewswire.comSecurities Fraud Class Action Filed Against Organon & Co. (OGN) – Levi & Korsinsky Reminds Investors of July 22, 2025June 11 at 9:00 PM | accessnewswire.comROSEN, A LONGSTANDING LAW FIRM, Encourages Organon & Co. Investors to Secure Counsel Before Important Deadline in Securities Class Action – OGNJune 11 at 8:32 PM | globenewswire.comOGN ALERT: Levi & Korsinsky Files Securities Fraud Class Action Against Organon & Co. - July 22, 2025 DeadlineJune 11 at 3:45 PM | accessnewswire.comROSEN, TRUSTED INVESTOR COUNSEL, Encourages Organon & Co. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OGNJune 11 at 3:30 PM | accessnewswire.comOrganon & Co. (OGN) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of July 22, 2025 DeadlineJune 11 at 2:00 PM | accessnewswire.comOrganon & Co. (OGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitJune 11 at 12:57 PM | prnewswire.comSecurities Fraud Class Action Filed Against Organon & Co. (OGN) - Levi & Korsinsky Reminds Investors of July 22, 2025June 11 at 11:30 AM | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Organon & Co. of Class Action Lawsuit and Upcoming Deadlines - OGNJune 11 at 9:00 AM | accessnewswire.comShareholders of Organon & Co. (OGN): Protect Your Rights Before July 22, 2025 - Contact Levi & KorsinskyJune 11 at 8:15 AM | accessnewswire.comOGN LEGAL REMINDER: Organon & Co. Securities Class Action Could allow Shareholders to Recover Losses; Contact BFA Law by July 22June 11 at 7:46 AM | accessnewswire.comSecurities Lawsuit Alert: Organon & Co. (OGN) - Contact Levi & Korsinsky Before July 22, 2025June 11 at 7:30 AM | accessnewswire.comOGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Organon & Co. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!June 11 at 7:00 AM | accessnewswire.comJuly 22, 2025 Deadline Approaching: Join Class Action Against Organon & Co. (OGN) - Contact Levi & KorsinskyJune 11 at 2:15 AM | accessnewswire.comOGN Investors Have Opportunity to Lead Organon & Co. Securities Fraud LawsuitJune 11 at 1:49 AM | prnewswire.comWedmont Private Capital Sells 54,982 Shares of Organon & Co. (NYSE:OGN)June 10 at 4:29 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingAnalysts Say Unilever Has the Leverage to Hit New HighsBy Thomas Hughes | May 15, 2025View Analysts Say Unilever Has the Leverage to Hit New HighsANAB, AAPG, OGN, and APLS Company DescriptionsAscentage Pharma Group International NASDAQ:AAPG$29.75 -0.15 (-0.50%) As of 06/11/2025 03:59 PM EasternAscentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.AnaptysBio NASDAQ:ANAB$23.60 -0.37 (-1.54%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$23.60 0.00 (0.00%) As of 06:49 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.Apellis Pharmaceuticals NASDAQ:APLS$19.27 -0.31 (-1.58%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$19.36 +0.09 (+0.47%) As of 07:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.Organon & Co. NYSE:OGN$10.10 +0.07 (+0.65%) Closing price 06/11/2025 03:59 PM EasternExtended Trading$10.02 -0.09 (-0.84%) As of 06:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why a Trump-Musk Feud Could Mean Big Wins for AST SpaceMobile Dave & Buster’s: Short-Covering Rally Signals Big Upside for PLAY GitLab: Buy It Low While You Still Can—Higher Prices Are Coming RKLB Breakout Fails Near Highs: Should Investors Be Concerned? Amazon Is on Track to Hit a Critical Level: Watch Out Tesla Stock: Why These 2 Downgrades Are Actually a Buy Signal The Other AI Chipmaker: Why Marvell's Dip Is a Buy Nintendo Stock Near Highs—Will the Switch 2 Keep the Rally Alive? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
